Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Actelion Ltd (ALIOF) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its pulmonary arterial hypertension (PAH) drug, Opsumit.

Actelion is looking to get Opsumit approved in the EU as monotherapy or in combination, for the long-term treatment of PAH in adults of WHO functional class II to III.

A final decision on Opsumit should be out in two months. With the CHMP adopting a positive opinion, we expect Opsumit to gain EU approval. It has also filed for approval in other regions.

The positive opinion was based on data from the SERAPHIN study. Results from the SERAPHIN study showed that the risk of a morbidity/mortality event was cut by 45% in patients who were administered Opsumit compared to those on placebo. The study also showed a reduction in the risk of PAH related hospitalization and death by 50% as compared to placebo.

A few days back, the U.S. Food and Drug Administration approved Opsumit 10 mg once daily for the treatment of PAH WHO Group I. Actelion will launch Opsumit in the U.S. in Nov 2013.

Opsumit is also being evaluated in a pivotal phase III program in patients suffering from digital ulcers associated with systemic sclerosis. Results from this study are expected in the first half of 2014. In addition, Opsumit is being evaluated for the treatment of glioblastoma (phase I).

We believe the Opsumit approval in the U.S. will strengthen Actelion’s cardiovascular portfolio. However, the PAH market looks extremely competitive with the presence of  Bayer’s (BAYRY - Analyst Report) Adempas, Pfizer Inc.’s (PFE - Analyst Report) Revatio and Gilead Sciences Inc.’s (GILD - Analyst Report) Letairis.

Actelion carries a Zacks Rank #1 (Strong Buy) while Bayer carries a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTERNATIONA ICAGY 33.30 +5.38%